Annual Total Liabilities
$1.64 B
+$233.30 M+16.64%
01 December 2023
Summary:
Sinovac Biotech annual total liabilities is currently $1.64 billion, with the most recent change of +$233.30 million (+16.64%) on 01 December 2023. During the last 3 years, it has risen by +$854.01 million (+109.32%). SVA annual total liabilities is now -43.07% below its all-time high of $2.87 billion, reached on 31 December 2021.SVA Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$1.39 B
-$245.27 M-15.00%
01 June 2024
Summary:
Sinovac Biotech quarterly total liabilities is currently $1.39 billion, with the most recent change of -$245.27 million (-15.00%) on 01 June 2024. Over the past year, it has dropped by -$245.27 million (-15.00%). SVA quarterly total liabilities is now -60.26% below its all-time high of $3.50 billion, reached on 30 June 2021.SVA Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -15.0% |
| 3 y3 years | +109.3% | -60.3% |
| 5 y5 years | +2000.4% | +1333.2% |
SVA Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -43.1% | +109.3% | -60.3% | +43.0% |
| 5 y | 5 years | -43.1% | +2000.4% | -60.3% | +1381.4% |
| alltime | all time | -43.1% | >+9999.0% | -60.3% | >+9999.0% |
Sinovac Biotech Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $1.39 B(-15.0%) |
| Dec 2023 | $1.64 B(+16.6%) | $1.64 B(+9.9%) |
| June 2023 | - | $1.49 B(+6.1%) |
| Dec 2022 | $1.40 B(-51.2%) | $1.40 B(+44.2%) |
| June 2022 | - | $971.93 M(-66.2%) |
| Dec 2021 | $2.87 B(+267.7%) | $2.87 B(-17.9%) |
| June 2021 | - | $3.50 B(+347.7%) |
| Dec 2020 | $781.20 M(+680.4%) | $781.20 M(+177.7%) |
| Sept 2020 | - | $281.31 M(+47.0%) |
| June 2020 | - | $191.38 M(+104.0%) |
| Mar 2020 | - | $93.83 M(-6.3%) |
| Dec 2019 | $100.10 M(+28.6%) | $100.10 M(+3.2%) |
| Sept 2019 | - | $96.98 M(+5.4%) |
| June 2019 | - | $92.04 M(+12.8%) |
| Mar 2019 | - | $81.56 M(+4.8%) |
| Dec 2018 | $77.85 M(-36.2%) | $77.85 M(-29.6%) |
| June 2018 | - | $110.54 M(-9.5%) |
| Dec 2017 | $122.08 M(+49.4%) | $122.08 M(+27.3%) |
| June 2017 | - | $95.87 M(+17.4%) |
| Dec 2016 | $81.69 M(+23.0%) | $81.69 M(+7.3%) |
| Sept 2016 | - | $76.12 M(+31.2%) |
| June 2016 | - | $58.00 M(-12.3%) |
| Mar 2016 | - | $66.12 M(-0.5%) |
| Dec 2015 | $66.42 M(-31.4%) | $66.42 M(+1.3%) |
| Sept 2015 | - | $65.55 M(-12.0%) |
| June 2015 | - | $74.49 M(+1.9%) |
| Mar 2015 | - | $73.12 M(-24.5%) |
| Dec 2014 | $96.80 M(-0.3%) | $96.80 M(-5.1%) |
| Sept 2014 | - | $102.05 M(+11.6%) |
| June 2014 | - | $91.47 M(-4.9%) |
| Mar 2014 | - | $96.20 M(-0.9%) |
| Dec 2013 | $97.05 M(+22.3%) | $97.05 M(+6.4%) |
| Sept 2013 | - | $91.19 M(-0.6%) |
| June 2013 | - | $91.73 M(+4.0%) |
| Mar 2013 | - | $88.22 M(+11.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $79.33 M(+12.3%) | $79.33 M(+5.0%) |
| Sept 2012 | - | $75.58 M(+2.4%) |
| June 2012 | - | $73.78 M(+3.9%) |
| Mar 2012 | - | $71.01 M(+0.6%) |
| Dec 2011 | $70.61 M(+6.0%) | $70.61 M(+6.5%) |
| Sept 2011 | - | $66.29 M(+11.7%) |
| June 2011 | - | $59.35 M(-7.2%) |
| Mar 2011 | - | $63.98 M(-3.9%) |
| Dec 2010 | $66.60 M(+9.2%) | $66.60 M(+26.4%) |
| Sept 2010 | - | $52.67 M(+21.6%) |
| June 2010 | - | $43.30 M(-26.8%) |
| Mar 2010 | - | $59.20 M(-3.0%) |
| Dec 2009 | $61.01 M(+131.9%) | $61.01 M(+13.7%) |
| Sept 2009 | - | $53.67 M(+4.1%) |
| June 2009 | - | $51.57 M(+114.1%) |
| Mar 2009 | - | $24.09 M(-8.4%) |
| Dec 2008 | $26.30 M(+7.2%) | $26.30 M(+10.5%) |
| Sept 2008 | - | $23.80 M(-11.2%) |
| June 2008 | - | $26.79 M(+15.7%) |
| Mar 2008 | - | $23.16 M(-5.7%) |
| Dec 2007 | $24.55 M(+56.3%) | $24.55 M(+21.9%) |
| Sept 2007 | - | $20.14 M(+16.8%) |
| June 2007 | - | $17.25 M(+9.8%) |
| Dec 2006 | $15.70 M(+36.4%) | $15.70 M(+34.5%) |
| June 2006 | - | $11.67 M(+1.4%) |
| Dec 2005 | $11.51 M(+67.8%) | $11.51 M(+73.3%) |
| June 2005 | - | $6.64 M(-3.2%) |
| Dec 2004 | $6.86 M(+71.0%) | $6.86 M(-12.3%) |
| Sept 2004 | - | $7.82 M(+3.6%) |
| June 2004 | - | $7.54 M(+88.1%) |
| Dec 2003 | $4.01 M(+2831.6%) | $4.01 M |
| Apr 2002 | $136.80 K(-85.6%) | - |
| Apr 2001 | $952.20 K(+61.4%) | - |
| Apr 2000 | $589.90 K(>+9900.0%) | - |
| Apr 1999 | $4500.00 | - |
FAQ
- What is Sinovac Biotech annual total liabilities?
- What is the all time high annual total liabilities for Sinovac Biotech?
- What is Sinovac Biotech quarterly total liabilities?
- What is the all time high quarterly total liabilities for Sinovac Biotech?
- What is Sinovac Biotech quarterly total liabilities year-on-year change?
What is Sinovac Biotech annual total liabilities?
The current annual total liabilities of SVA is $1.64 B
What is the all time high annual total liabilities for Sinovac Biotech?
Sinovac Biotech all-time high annual total liabilities is $2.87 B
What is Sinovac Biotech quarterly total liabilities?
The current quarterly total liabilities of SVA is $1.39 B
What is the all time high quarterly total liabilities for Sinovac Biotech?
Sinovac Biotech all-time high quarterly total liabilities is $3.50 B
What is Sinovac Biotech quarterly total liabilities year-on-year change?
Over the past year, SVA quarterly total liabilities has changed by -$245.27 M (-15.00%)